ABEO

Abeona Therapeutics, Inc. · NASDAQ

Performance

-3.55%

1W

-3.23%

1M

-1.72%

3M

+25.55%

6M

+13.77%

YTD

+20.51%

1Y

Profile

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in New York, New York.

Technical Analysis of ABEO 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with a Moving Average Score of 16 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance. Overall, the Technical Score of 36 reinforces the bearish outlook, signaling caution for potential investors.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of ABEO

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.